The aim of this report is to assess the added benefit of dimethyl fumarate (DMF) in comparison with the appropriate comparator therapy (ACT) in adult patients with relapsing remitting multiple sclerosis (RRMS).
http://ift.tt/2ssnHro
Τετάρτη 14 Ιουνίου 2017
Dimethyl Fumarate -- Benefit Assessment According to §35a Social Code Book V [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
-
http://ift.tt/2sxENoo
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου